Celgene (CELG) Presents Data on Two REVLIMID + Rituximab Studies StreetInsider.com (subscription) Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from two studies evaluating the combination of REVLIMID (lenalidomide) and rituximab in various non-Hodgkin's lymphomas were ... |
